Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
Xiaoyan Wu,1 Lin Wang,1 Yining Qiu,1 Bingyu Zhang,1 Zhenhua Hu,2 Runming Jin1 1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 2Department of Pharmacy, Shanghai Jiao Tong University, Shanghai, China Abstract: T cell acute lymp...
Main Authors: | Wu X, Wang L, Qiu Y, Zhang B, Hu Z, Jin R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-10-01
|
Series: | International Journal of Nanomedicine |
Subjects: | |
Online Access: | https://www.dovepress.com/cooperation-of-irak14-inhibitor-and-abt-737-in-nanoparticles-for-syner-peer-reviewed-article-IJN |
Similar Items
-
Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
by: Alexey Lomovsky, et al.
Published: (2020-11-01) -
ABT-737 synergizes with Bortezomib to kill melanoma cells
by: Steven N. Reuland, et al.
Published: (2012-02-01) -
The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
by: Denis V. Baev, et al.
Published: (2014-01-01) -
The inhibition of Beclin1-dependent autophagy sensitizes PTC cells to ABT737-induced death
by: Ning Hu, et al.
Published: (2024-03-01) -
BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome
by: Petra Gorombei, et al.
Published: (2021-09-01)